Royalty Report: Drugs, Therapeutic, Disease – Collection: 273253

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 15

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 15

Primary Industries

  • Drugs
  • Therapeutic
  • Disease
  • Vaccine
  • HIV / AIDs
  • Diagnostic
  • Diabetes Treatment
  • Genome
  • obesity
  • DNA
  • ribonucleic acid
  • Cancer
  • Biotechnology
  • Optical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 273253

License Grant
Medical School and Licensor each hereby grants to Company and its Affiliates an exclusive, worldwide, royalty-bearing license (with the right to sublicense) under their respective commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.
                                                                    
Medical School hereby grants to Company and its Affiliates a non-exclusive, royalty-bearing license (with the right to sublicense) under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field and Licensor hereby consents to such grant by Medical School.

Licensor hereby grants to Company and its Affiliates the right to acquire a non-exclusive, worldwide, royalty-bearing license (with the right to sublicense) to any Licensor Related Technologies. Licensor shall promptly disclose in writing to Company each of the Licensor Related Technologies at the time such technologies are acquired or licensed by Licensor. Licensor and Company shall negotiate in good faith the terms of the Licensor Related Technologies License.

License Property
United States Provisional Patent Application filed December 3, 2002 serial number 60/430,732 entitled ' Polyvalent, Primary HIV-1 Envelope Glycoprotein DNA Vaccine.

United States Provisional Patent Application filed in September 2003, serial number 60/503/907 entitled 'Polyvalent DNA and Protein Vaccines.'

United States Utility Patent Application filed December 3, 2003 and its foreign counterparts referred to by the parties as the Joint Patent Filing.

Licensed Product means the HIV Vaccine and any product that cannot be developed, manufactured, used, or sold without (a) infringing one or more claims under the Patent Rights, (b) using or incorporating some portion of one or more Biological Materials, or (c) using some portion of the Related Technology.

Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights, which materials are described, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA,  recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials (such as recombinant proteins isolated from a cell extract or supernatant by non-proprietary affinity purification methods). These Biological Materials shall be listed on this agreement, which will be periodically amended to include any additional Biological Materials that Medical School may furnish to Company.

Licensor Related Technologies means any additional technologies outside of the 03-24 Technology and the 03-111 Technology that satisfies all of the following (i) are now or subsequently owned or licensed to Licensor, including any technologies that may be acquired by Licensor pursuant to its option for an exclusive license of the Medical School Subcontract, (ii) result from work done by Medical School under the Medical School Subcontract for a DNA-based HIV vaccine with protein boost, and (iii) are deemed necessary or advantageous by Company for the development or commercialization of the HIV Vaccine.

The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by Medical School and Licensor as UMMC 03-111.

The '03-24 Technology – UMMC 03-24 entitled Primary and Polyvalent HIV-1 Envelope Glycoprotein DNA Vaccines

Field of Use
Field means therapeutics and prophylactics limited to the generation of DNA-based HIV-1 vaccines.

IPSCIO Record ID: 273729

License Grant
The parties agree that upon the Joint Patent Filing, the 03-111 Technology shall become part of the Patent Rights as defined in the 03-24 License Agreement. Licensee agrees that the inclusion of the 03-111 Technology into the 03-24 License Agreement shall occur without further compensation to University or Licensee, except as specified in this Agreement, and at no additional cost to Licensor.  Licensee shall also grant Licensor a non-exclusive, royalty-bearing license to any additional technologies outside of the 03-24 Technology and the 03-111 Technology that are owned or licensed to Licensee (including those acquired by Licensee pursuant to its right of first refusal under the University Subcontract) and that result from work done by University under the University Subcontract for a DNA-based HIV vaccine with protein boost and that are necessary or advantageous to Licensor for the development or commercialization of the HIV Vaccine, with the amount of the royalty to be established in the Definitive Collaborative Agreement and to be negotiated in good faith by the parties. University shall grant Licensor a right of first negotiation to obtain a royalty-bearing license to University exclusive or non-exclusive rights to any additional technology outside of the 03-24 Technology and 03-111  technology that are owned by University and have not been acquired or licensed to Licensor pursuant to its right of first refusal under the University Subcontract and that result from work done under the University Subcontract and that are necessary or advantageous to Licensor for the development or commercialization of the HIV Vaccine. Licensee shall represent that it does not currently own or have any other rights to any other technology that would be infringed by the development or commercialization of the HIV Vaccine.
License Property
The '03-24 Technology – U.S. Patent Application Serial Number 60/430,732 (the '03-24 Patent Filing') with the United States Patent and Trademark Office covering a foundational HIV vaccine technology invention referred to by University as UMMC 03-24.

The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by University and Licensee as UMMC 03-111.

Field of Use
The HIV vaccine technology that Licensee have licensed is based upon a unique mixture of human HIV-1 primary isolates from several genetic subtypes of HIV. This polyvalent naked DNA (isolated, purified DNA) vaccine approach has the potential advantages of maintaining efficacy despite the high mutation rate of HIV, a broader immune response against divergent HIV-1 glycoproteins and the possible ability to neutralize a wide spectrum of HIV-1 viruses.

IPSCIO Record ID: 275801

License Grant
Licensor grants sublicense rights to the Patent Rights, granted to Licensor in the Amended and Restated Exclusive License Agreement, under said rights to make, have made, use, manufacture and sell products using the Joint Patent Filing technology.
License Property
Licensor has been granted worldwide exclusive license to the Joint Patent Filing, which includes the 03-24 Technology and 03-111 Technology.

Licensed Product shall mean any HIV vaccine product other than the HIV Vaccine that cannot be developed, manufactured, used, or sold without infringing one or more Valid Claim under the Patent Rights.

The patents are titled Polyvalent, Primary HIV -1 Envelope Glycoprotein DNA Vaccine, and, Polyvalent DNA and Protein Vaccines.

This technology is a DNA-based HIV vaccine that incorporates the 03-24 Technology and the 03-111 Technology.  Invention disclosure number 03-24 is entitled Primary and Polyvalent IIlV-1 Envelope Glycoprotein DNA Vaccines.  And HIV protein boost technology invention is referred to as 03-111.

New Vaccine shall mean any HIV vaccine other than the HIV Vaccine.

Field of Use
The Field shall mean all HIV vaccines.

IPSCIO Record ID: 233429

License Grant
University grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.
University grants to Company and its Affiliates a non–exclusive license, with the right to sublicense,  under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.
License Property
The patents are for Primary and Polyvalent HIV-1 Envelope Glycoprotein DNA Vaccines.  Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, using or incorporating some portion of one or more Biological Materials, or using some portion of the Related Technology.

Related Technology means any know-how, technical information, research and development information, test results, and data necessary for the effective exercise of the Patent Rights which has been developed in a laboratory at the Medical School as of the Effective Date and which is owned by Medical School.

United States Provisional Patent Application filed December 3, 2002 serial number 60/430,732 entitled “ Polyvalent, Primary HIV-1 Envelope Glycoprotein DNA Vaccine.

Field of Use
The Field means therapeutics and prophylactics limited to the generation of DNA-based primary and polyvalent HIV-I envelope vaccines.

IPSCIO Record ID: 273254

License Grant
The parties agree that upon the Joint Patent Filing, the 03-111 Technology shall become part of the Patent Rights as defined in the 03-24 License Agreement. Licensor agrees that the inclusion of the 03-111 Technology into the 03-24 License Agreement shall occur without further compensation to University or Licensor, except as specified in this Agreement, and at no additional cost to Licensee.  Licensor shall also grant Licensee a non-exclusive, royalty-bearing license to any additional technologies outside of the 03-24 Technology and the 03-111 Technology that are owned or licensed to Licensor (including those acquired by Licensor pursuant to its right of first refusal under the University Subcontract) and that result from work done by University under the University Subcontract for a DNA-based HIV vaccine with protein boost and that are necessary or advantageous to Licensee for the development or commercialization of the HIV Vaccine, with the amount of the royalty to be established in the Definitive Collaborative Agreement and to be negotiated in good faith by the parties. University shall grant Licensee a right of first negotiation to obtain a royalty-bearing license to University exclusive or non-exclusive rights to any additional technology outside of the 03-24 Technology and 03-111  technology that are owned by University and have not been acquired or licensed to Licensee pursuant to its right of first refusal under the University Subcontract and that result from work done under the University Subcontract and that are necessary or advantageous to Licensee for the development or commercialization of the HIV Vaccine. Licensor shall represent that it does not currently own or have any other rights to any other technology that would be infringed by the development or commercialization of the HIV Vaccine.
License Property
The '03-24 Technology – U.S. Patent Application Serial Number 60/430,732 (the '03-24 Patent Filing') with the United States Patent and Trademark Office covering a foundational HIV vaccine technology invention referred to by University as UMMC 03-24.

The '03-111 Technology – U. S. Patent Application Serial Number 60/503,907 (the '03-111 Patent Filing') covering an HIV protein boost technology invention referred to by University and Licensor as UMMC 03-111.

Field of Use
This agreement pertains to HIV vaccine.

IPSCIO Record ID: 243427

License Grant
The University grants to the Licensee a non-exclusive, worldwide, royalty-bearing license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.  Licensee shall have the right to grant sublicenses.
License Property
The patents are for RNA Sequence-Specific Mediators of RNA Interference.

Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, or, using or incorporating some portion of one or more Biological Materials.

Biological Materials means the tangible biological materials described in the patents, as well as tangible materials that are routinely produced through use of the original materials, including, for example, any progeny derived from a cell line, monoclonal antibodies produced by hybridoma cells, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of isolated DNA or RNA, and substances routinely purified from a source material included in the original materials.

UMMC 01-36 “RNA Sequence-Specific Mediators of RNA Interference” Inventors David P. Bartel, Philip A. Sharp, Thomas Tuschl, and Philip D. Zamore
I. United States Patents and Application
USSN 60/265232 entitled “RNA Sequence-Specific Mediators of RNA Interference”

USSN 09/821832 entitled “RNA Sequence-Specific Mediators of RNA Interference”
PCT/US01/10188 entitle “RNA Sequence-Specific Mediators of RNA Interference”

Field of Use
The field of use is therapeutics limited to the narrowed fields of other Medical School license agreements; specifically, using RNAi to inhibit HCMV Immediate Early (IE) gene expression in Retinitis applications, using RNAi to inhibit mutant SOD 1 gene expression in Amytrophic Lateral Sclerosis (ALS) applications, and using RNAi to inhibit gene targets implicated in Type II Diabetes and Obesity under the rights of Medical School in any patent rights claiming those inventions.

IPSCIO Record ID: 230810

License Grant
The University Medical School hereby grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.
License Property
Medical School is owner by assignment of the invention claimed in the United States Patent Application pertaining to the Medical Schools invention titled Inhibition of Gene Expression in Adipocytes using Interference RNA.

Patent Rights
Docket number UMMC 03-05 Title “ Method of Introducing SI RNA into adipocytes”
Provisional Patent Application Serial number 60/432,427, filed on December 11, 2002.

Field of Use
The Field means drug discovery in type 2 diabetes and/or obesity with therapeutic, prophylactic, or diagnostic applications.

IPSCIO Record ID: 25776

License Grant
The Licensor grants to the Licensee and its Affiliates an exclusive, worldwide license, with the right to sub-license, under the Licensor’s commercial rights in the Patent Rights and Biological Materials to develop, make, use and sell Licensed Products in the field.
License Property
Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights, as well as tangible materials that are routinely produced through use of the original materials, including for example, any progeny derived or produced from a cell line, monoclonal antibodies produced by hybridoma cell, DNA or RNA replicated from isolated DNA or RNA, recombinant proteins produced through use of DNA or RNA, and substances routinely purified from a source material included in the original materials such as recombinant proteins isolated from a cell extract or supernantant by non-proprietary affinity purification methods.

Pursuant to the new Agreement, the Licensor has granted an exclusive, worldwide,  (with the right to subLicense) License with regard to patents entitled Use of Fused Imidazoles, Aminopyrimidines, Isonicotinamides, Aminomethyl Phenoxypiperidines and Aryloxypiperidines to Promote and Detect Endogenous Neurogenesis (U.S. Patent Application No. 10/914,460 ); and Methods for Discovering Neurogenic Agents ( U.S. Patent Application No. 10/728,652 ).

Field of Use
Field means the use of compounds as therapeutic agents to treat diseases in humans and animals in all therapeutic categories including, without limitation  Category I, which is limited to psychiatric disorders, mood disorders, depression, post-traumatic stress syndrome, anxiety, panic disorder, bipolar and unipolar disorders, delusional disorders, and schizophrenia;  Category II, which includes Alzheimer’s Disease and Parkinson’s Disease;  and Category III, which includes diabetes and its complications, including the neurological complications of peripheral neuropathies, static and progressive dementias and hypokinetic movement disorders.

IPSCIO Record ID: 233431

License Grant
University grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.

University grants to Company and its Affiliates a non-exclusive license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.

License Property
The patent is for Selective Silencing of a Dominant ALS Gene by RNAi.  Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, using or incorporating some portion of one or more Biological Materials, or using some portion of the. Related Technology.

Related Technology means any know-how, technical information, research and development information, test results, and data necessary for the effective exercise of the Patent Rights.

Docket number UMMC 03-60 Title “Selective Silencing of a Dominant ALS Gene by RNAi”
Patent Application Serial number 60/423,507, filed on November 4, 2002

Field of Use
The Field means inhibition of mutant superoxide dismutase (SODI) gene expression for the treatment of amyotrophic lateral sclerosis (ALS) including therapeutics, prophylactics and diagnostics.

IPSCIO Record ID: 233430

License Grant
University grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.

University grants to Company and its Affiliates a non-exclusive license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.

License Property
The patent is for Novel Gene-Based Therapeutics for Solid Tumor Treatments. Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, using or incorporating some portion of one or more Biological Materials, or using some portion of the Related Technology.

Related Technology means any know-how, technical information, research and development information, test results, and data necessary for the effective exercise of the Patent Rights which has been developed in a laboratory at the Medical School as of the Effective Date and which is owned by Medical School.

United States Provisional Patent Application in preparation pertaining to the Medical School invention disclosure number UMMC 03-36 entitled Novel Gene Based Therapeutics for Solid Tumor Treatments.

Field of Use
The Field means therapeutics and prophylactics limited to the delivery of plasmid DNAs encoding IL-2, IL-10 and Apo-2 ligand genes into solid prostate.

IPSCIO Record ID: 233428

License Grant
University hereby grants to Company and its Affiliates an exclusive, worldwide license,with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.

University hereby grants to Company and its Affiliates a non-exclusive license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field.

License Property
The patents are for RNAi Targeting of Viruses.  Licensed Product means any product that cannot be developed, manufactured, used, or sold without infringing one or more claims under the Patent Rights, using or incorporating some portion of one or more Biological Materials, or using some portion of the Related Technology.

Biological Materials means certain tangible biological materials that are necessary for the effective exercise of the Patent Rights.

Related Technology means any know-how, technical information, research and development information, test results, and data necessary for the effective exercise of the Patent Rights which has been developed in the laboratory at the Medical School as of the Effective Date and which is owned by Medical School.

UMMC 03-17 “RNAi Targeting of Viruses”

Field of Use
The Field means the limited use of RNAi to inhibit human cytomegalovirus (HCMV) Immediate Early (IE) gene expression for the development of retinitis prophylactics, therapeutics, and diagnostics.

IPSCIO Record ID: 237242

License Grant
Each of the Parties agree to perform the work designated in the Work Plan and Budget to be performed by it, respectively, in the course of the Research and Development Program substantially within the time frames designated in the Work Plan and Budget.  Licensee will act as the primary Vaccine Developer under the Work Plan and Budget. Licensor and Licensee will be entitled to involve one or more subcontractors in the performance of such work, provided that each such subcontractor is approved in writing for such purpose by all parties to this Agreement, which approval shall not be unreasonably withheld or delayed. Licensor acknowledges that later steps and phases of work in the Research and Development Program, and the time frames therefor, will depend in part upon the results achieved in earlier steps and phases. The responsibility of Licensor and Licensee hereunder shall be satisfied by their devotion to the Research and Development Program of the efforts called for from them, respectively, in the Work Plan and Budget; neither of Licensor nor Licensee warrants or commits that it will achieve successful or timely results in the conduct of the Research and Development Program.
License Property
Program Inventions shall mean inventions, discoveries, and improvements, patentable or unpatentable, first conceived or reduced to practice by Licensor, Licensee, Licensor, or the subcontractors of any of them during and in the course of work under the Research and Development Program, inclusive of any cell lines or other materials first developed in the course of such work under the Research and Development Program.

Licensee-Controlled Inventions shall mean the inventions disclosed in the United States patents and foreign equivalents and United States and foreign patent applications listed and all divisions, continuations, continuations in part, reissues, or extensions thereof, any periods of marketing exclusivity relating thereto, and any letters patent that issue thereon. It is understood that certain of the Licensee-Controlled Inventions (the Licensed Licensor Rights) are owned by Licensor and are covered by one or more exclusive licenses or sublicenses to Licensee, directly or indirectly.

US 5,858,775 – Adeno-associated virus materials and methods
US 5,786,211 – Adeno-associated virus materials and methods
US 5,658,785 – Adeno-associated virus materials and methods
US 5,139,941 – AAV transduction vectors

Program Vaccines shall mean any AAV (adeno-associated virus) particle-based vector that contains an HIV-1 gene in the recombinant vector genome and that can act as a prophylactic vaccine against HIV-1.

Proprietary Technology shall mean any Background Technology to the extent it has not previously been disclosed in an issued patent or a published patent application. Background Technology shall mean (i) the rights to make, use, sell, offer for sale, and import the Licensee-Controlled Inventions; (ii) all inventions (whether or not patented or patentable), know-how, techniques, cell lines, data, studies and results of studies and other proprietary information in the possession or control of Licensor at the Effective Date and at any time thereafter during the period in which Licensor remains a direct participant in the Research and Development Program, to the extent bearing upon the Program Vaccines, the Licensee-Controlled Inventions, the Program Inventions, or any of them within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensor); and (iii) know-how and other proprietary information in the possession or control of Licensee at the Effective Date and at any time thereafter during the period in which Licensee remains a direct participant in the Research and Development Program, to the extent useful for the practice of the Licensee-Controlled Inventions within the Program Field (as and to the extent the Program Field exists during the period of such direct participation by Licensee).

Work Plan and Budget shall mean the set of tasks, procedures, protocols, standards, budgets, and target time frames set forth, as such may be amended or supplemented by mutual written agreement of the parties from time to time.

Field of Use
This agreement pertains to the drug industry primarily relating to vaccine development.

Program Field shall mean the manufacture of one or more of the Program Vaccines through the use of the particular combination of Program Inventions and Background Technology as implemented by Licensor and Licensee under this Agreement during and in the course of the Research and Development Program (as the same may be supplemented or improved by or for Licensor with other inventions or technology from sources other than Licensor or Licensee), solely for distribution in the Public Sector, and the use, sale, offer for sale, and import of such Program Vaccines so manufactured in and to the Public Sector. I

The collaboration agreement is to develop a vaccine to prevent AIDS. The vaccine will utilize Targeted Genetics’ Adeno-Associated  Viral Vectors (AAV ) to deliver HIV genes as a novel form of genetic immunization.

IPSCIO Record ID: 230807

License Grant
For the License Grants of Patent Rights and Biological Materials, the University/Medical School grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field and to develop and perform Licensed Services in the Field.

For the Related Technology, Medical School grants to Company and its Affiliates a non-exclusive, license, with the right to sublicense, under its commercial rights in the Related Technology to develop, make, have made, use, and sell Licensed Products in the Field and to develop and perform Licensed Services in the Field.

License Property
Patents include Method of Introducing SI RNA into adipocytes, Genes Expressed in Type II diabetes and Uses Thereof, and, Receptor-Activated Reporter Systems.  Related  Technology  means  know-how,  technical  information, research and development  information,  test results, and data necessary for the
effective  exercise of the Patent  Rights which are owned by the Medical  School.

Licensed Product means any Covered Product or Developed Product.

Covered Product means any product that cannot be manufactured, used, or sold without infringing one or more claims under the Patent Rights, incorporates some portion of one or more Biological Materials proprietary to Medical School, or  cannot be manufactured, used, or sold without using some portion of the Related Technology.

Developed Product means any product that is not a Covered Product and is developed using methods claimed in the Patent Rights or using some material portion of the Related Technology.

Licensed Service means any service that cannot be developed or performed without using at least one process that infringes one or more claims under the Patent Rights,  uses some portion of one or more Biological Materials, or  uses some portion of the Related Technology.

Field of Use
Field means drug discovery in type 2 diabetes and/or obesity with therapeutic, prophylactic, or diagnostic applications and products for treatment, prevention or diagnosis of type 2 diabetes and/or obesity.

IPSCIO Record ID: 364010

License Grant
Licensor hereby grants to Licensee and exclusive license. Subject to any rights of the U.S. government specified in this agreement, in the Territory for the Field of Use, with the right to sublicense, under the Patent Rights, to make, have made for its own use and sale, use and sell Licensed Products and Licensed Processes.  

Licensor also hereby grants to Licensee an exclusive license to make. use. and/or sell the Licensed Materials in the Territory for Field of Use.  At Licensee’s request, Licensor shall provide Licensee with a reasonable amount of Licensed Materials so that Licensee may reproduce such Licensed Materials for the purpose of making, selling, or using Licensed Products or Licensed Processes.

Licensor grants to Licensee a six (6) month exclusive option to negotiate a worldwide royalty-bearing, exclusive license with right to sublicense for any Improvement.

License Property
The Podack Cancer Vaccine (UM97-14) technology shall mean the technology relating to a cell-based vaccine for treating cancer patients utilizes human cancer cells that have been engineered to secrete gp96.  The presently preferred version of the vaccine uses the AD100 human lung adrenocarcinoma cell line transfected with constructs that encode III.A-AI and gp96-Ig (heat shock protein gp96 fused to Fe region of IgGI).  In a presently preferred protocol, NSCLC patients are intradermermally administered several injections of 5×107 vaccine cells each at two week intervals.

Licensed Product shall mean any product or part thereof which
(a) is covered in whole or in part by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights
(b) is manufactured by using a process which is covered in whole or in party by an issued, unexpired, and not adjudicated unenforceable claim or a pending claim contained in the Patent Rights or
(c) incorporated or comprises the Podack Cancer Vaccine (UM97-14) or the cell line “AD100-gp96/III.A”.

Patent Rights shall mean the following United States Patent applications  U.S. provisional patent application serial number 60/075.358 entitled “Modified Heat Shock Protein-antigenic Peptide Complex” and filed on February 20, 1998  U.S. patent application serial number 09 253.439 entitled “Modified Heat Shock Protein-Antigenic Peptide Complex” and filed on February 19, 1999  U.S. patent  application serial number 11/878.460 entitled “Recombinant Cancer Cell Secreting Modified Heat Shock Protein-antigenic Peptide Complex” and filed on July 24, 2008  all United States patents and foreign patents and patent applications based on these U.S. applications  all divisionals, continuations of the foregoing  and those claims in continuations-in-part of the foregoing that are described in sufficient detail in U.S. provisional patent applications serial number 60/075.358.  U.S. Patent application serial number 09 253.439, or U.S. patent application serial number 11/878.460 to meet the requirements of 35 U.S.C. 112¶1; and any re-examinations or reissues of the foregoing.  â€œPatent Rights” shall not include Excluded Patent Rights.

Licensed Materials shall mean any modified AD100 cell lines that have been engineered to secrete gp96.

Field of Use
Field of Use is for treating cancer patients and shall mean all human healthcare and research applications.

IPSCIO Record ID: 230809

License Grant
The University Medical School grants to Company and its Affiliates an exclusive, worldwide license, with the right to sublicense, under its commercial rights in the Patent Rights and Biological Materials to develop, make, have made, use, and sell Licensed Products in the Field.
License Property
Medical School is owner by assignment of the invention claimed in the United States Patent Application pertaining to the Medical Schools invention entitled In Vivo Production of Small Interfering RNAs.

UMMC 02-01 “In Vivo Production of Small Interfering RNAs”
Inventors

Phillip Zamore, Craig Mello, Gyorgy Hutvagner, Juanita McLachlan, and Alla Grishock

Provisional Patent Application filed on July 12, 2001 #60/305,185 entitled “In Vivo Production of Small Interfering RNAs that Mediate Gene Silencing”
U.S. Patent Application filed on July 12, 2002 #10/195,034

Field of Use
The Field means therapeutics, prophylactics, and diagnostics arising from the limited use of RNAi to inhibit HCMV Immediate Early (IE) gene expression in Retinitis applications, using RNAi to inhibit mutant SOD I gene expression in Amyotrophic Lateral Sclerosis (ALS) applications, and using RNAi to inhibit gene targets implicated in Type II Diabetes and Obesity.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.